Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
Rhea-AI Summary
Polaryx Therapeutics (Nasdaq: PLYX) announced that the U.S. FDA has granted Fast Track Designation to PLX-200 for CLN3 (JNCL), Krabbe disease, and Sandhoff disease, joining prior FTD for CLN2.
With FTD across all four targeted indications, PLX-200 will be studied in the SOTERIA Phase 2 basket trial, which the company plans to advance into the clinic in the second half of 2026.
Positive
- Fast Track designation granted for four indications (CLN2, CLN3, Krabbe, Sandhoff)
- SOTERIA Phase 2 will evaluate PLX-200 across multiple LSDs starting H2 2026
- Regulatory alignment may enable more frequent FDA interactions and potential rolling review
Negative
- No clinical efficacy data for PLX-200 reported in this announcement
- Phase 2 trial status means clinical benefit remains unproven and development risk persists
News Market Reaction – PLYX
In the Apr 21 session, PLYX declined 7.54%, reflecting a notable negative market reaction. Argus tracked a peak move of +24.9% during that session. Argus tracked a trough of -14.8% from its starting point during tracking. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 15 | Industry award | Positive | -0.1% | Recognition for excellence in pediatric care and LSD platform approach. |
| Apr 01 | Conference participation | Neutral | +0.5% | Participation in Needham healthcare conference with investor meetings and webcast. |
| Mar 17 | Fast Track granted | Positive | -0.9% | FDA Fast Track Designation for PLX‑200 in CLN2 supporting SOTERIA trial. |
| Mar 12 | Community outreach | Positive | -19.3% | Krabbe community engagement events and advancement of SOTERIA Phase 2 trial. |
| Feb 27 | Corporate commitment | Positive | -4.4% | Rare Disease Day message and focus on advancing SOTERIA Phase 2 trial. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive corporate and regulatory milestones have often coincided with flat-to-negative next-day price moves, suggesting a pattern of muted or contrarian reactions to favorable news.
Over the past few months, Polaryx highlighted its rare pediatric LSD focus through multiple milestones. On Feb 27, it reaffirmed commitment to LSD patients while advancing the SOTERIA Phase 2 trial. Subsequent news deepened Krabbe community engagement on Mar 12 and announced FDA Fast Track for PLX‑200 in CLN2 on Mar 17, followed by an investor conference and a Pinnacle award in April. Despite the generally positive tone of these updates, share reactions were often negative, similar to today’s Fast Track expansion.
Key Terms
fast track designation regulatory
fast track program regulatory
rolling review regulatory
phase 2 medical
basket trial medical
marketing application regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II).
Following the March 2026 grant of FTD to PLX-200 in treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease), PLX-200 now holds FTD for all four prospective indications to be studied in the SOTERIA Phase 2 basket trial.
The Fast Track program is designed to facilitate and expedite the review of therapies intended to treat serious or life-threatening conditions with unmet medical need. Companies receiving Fast Track Designation may benefit from more frequent interactions with the FDA and the potential for rolling review of a future marketing application.
“We are delighted by the FDA’s decision to further extend Fast Track Designation to CLN3, Krabbe disease, and Sandhoff disease,” said Alex Yang, Chair and Chief Executive Officer of Polaryx Therapeutics. “As we prepare to advance the SOTERIA Phase 2 basket trial, receiving this designation across all four indications underscores the enormous need that exists in the current LSD landscape while also recognizing PLX-200’s potential to meaningfully address treatment gaps across multiple LSDs.”
“CLN2 disease, CLN3 disease, Krabbe disease, and Sandhoff disease are devastating neurodegenerative conditions with limited or no disease‑modifying treatment options. The regulatory alignment received from the FDA’s Fast Track Designations highlight the seriousness of these disorders and the need for new therapeutic options like PLX-200,” said Lisa L. Bollinger, M.D., Chief Medical Officer of Polaryx Therapeutics. “We remain focused on preparing the SOTERIA trial to advance PLX‑200 into the clinic in the second half of 2026.”
About PLX-200
Polaryx’s lead drug candidate, PLX-200, is an orally available compound comprised of gemfibrozil. Gemfibrozil is an FDA-approved lipid regulating agent in the fibrate family which has only been approved in a capsule form for adult patients with very high elevations of serum triglyceride levels to decrease serum triglycerides and very low-density lipoprotein cholesterol and increase high density lipoprotein cholesterol. The ability of gemfibrozil to cross the blood-brain barrier (BBB) has also been documented in third-party preclinical trials and safe use of gemfibrozil in adults has also been well-established over several decades of clinical investigation and commercial use, which we believe accelerates clinical development and reduces associated costs. We believe the unique ability of PLX-200 to cross the BBB, along with its widely applicable mechanism of action, positions PLX-200 to potentially address the immense unmet need in multiple rare, catastrophic LSD indications.
About the SOTERIA Trial
SOTERIA is a Phase 2, open-label, single arm trial intended to assess the safety, tolerability, and clinical activity of Polaryx’s lead drug candidate, PLX-200, in CLN2, CLN3, Krabbe disease, and Sandhoff disease, four different LSDs whose patient populations Polaryx believes represent approximately one quarter of the LSD population. SOTERIA is designed to be flexible, resource-efficient, and provide important data and information important to PLX-200’s future clinical development. Polaryx received a safe to proceed letter in October 2025 from the FDA and plans to initiate SOTERIA in the second half of 2026 in trial sites in the United States as well as in Europe and Asia or other foreign jurisdictions. Designed with a high degree of flexibility, SOTERIA represents a resource-efficient opportunity to validate PLX-200’s preclinical science across multiple LSDs while gathering data that will be invaluable in planning PLX-200’s future development pathway, including the initiation of potentially pivotal trials. For the CLN2 and CLN3 cohorts, although the entire trial is open label, these cohorts will incorporate analyses comparing natural history data as a control arm to PLX-200’s treated arm. A natural history study is a preplanned observational study intended to track the course of the disease. Should the data demonstrate compelling clinical activity, Polaryx may seek conditional marketing authorization.
About CLN3 Disease
CLN3 disease, also known as juvenile neuronal ceroid lipofuscinosis (JNCL) or juvenile Batten disease, is a rare inherited LSD that primarily affects the nervous system in childhood. With a prevalence of one in 100,000 births worldwide, CLN3 disease is caused by mutations in the CLN3 gene which encodes a lysosomal transmembrane protein, Battenin. The most common genetic defect is a ~1-kb deletion in CLN3, leading to a loss of protein function. The disorder follows an autosomal recessive inheritance pattern, requiring two defective copies of CLN3 for disease manifestation. Due to impaired lysosomal function, neurons accumulate waste material and progressively deteriorate, resulting in a neurodegenerative disease course.
About Krabbe Disease
Krabbe disease, also known as globoid cell leukodystrophy, is caused by mutations in the galactosylceramidase (GALC) gene, leading to GALC deficiency and an inability to break down certain lipids in the body. This results in accumulation of toxic substances in the brain and other areas of the nervous system leading to demyelination and severe neurological decline. The incidence rate of Krabbe disease varies significantly, affecting 0.3 to 2.6 per 100,000 live births. We believe that there are approximately 6,700 Krabbe disease patients in the United States, Europe and select regions of the ROW. Hematopoietic stem cell transplantation (HSCT) is considered the current standard of care.
About Sandhoff Disease
Sandhoff disease, a more severe form of Tay-Sachs disease, is caused by mutations in the HEXB gene, which impair the function of β-hexosaminidase enzymes. This deficiency causes the accumulation of GM2 gangliosides in neurons, resulting in progressive neurodegeneration. Several subtypes of Sandhoff disease exist, varying depending on the age of onset. The infantile form typically manifests between three and six months of age and is the most severe. The first symptom is often hypotonia, accompanied by an exaggerated startle response to auditory stimuli, followed by developmental regression. Acute infantile and sub-acute juvenile Sandhoff disease patients begin regressing significantly after the onset of symptoms, with death usually occurring between two and three years for the infantile cohort and early to late teens for the juvenile cohort. Life expectancy for late-onset Sandhoff patients is not significantly impacted. We believe that there are approximately 1,200 Sandhoff disease patients in the United States, Europe and select regions of the ROW.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements regarding: Polaryx’s clinical development plans for PLX-200, including the timing for initiation of the SOTERIA trial. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Polaryx believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Polaryx’s filings with the U.S. Securities and Exchange Commission (the SEC), many of which are beyond the company’s control and subject to change. Actual results could be materially different. Risks and uncertainties include: global macroeconomic conditions and related volatility, expectations regarding the initiation, progress, and expected results of Polaryx’s clinical trials; expectations regarding the timing, completion and outcome of Polaryx’s clinical trials; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in Polaryx’s most recently filed Form 10-K with the SEC and subsequent disclosure documents Polaryx may file with the SEC. Polaryx claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Polaryx expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.
Media Contact:
CORE IR
(212) 655-0924
media@polaryx.com
Investor Contact:
CORE IR
(212) 655-0924
investor@polaryx.com
